Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   133 Trials   133 Trials   6536 News 


12345678910111213...7778»
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal, HEOR:  Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis. (Pubmed Central) -  May 16, 2024   
    In this cohort of almost half-a-million treatment-naive women with PMO, we observed clinically significant reductions in the risk of MOP, hip, NV, NHNV, and HV fractures for patients on denosumab compared with alendronate. Patients who remained on denosumab for longer periods of time experienced greater reductions in fracture risk.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Osteoporosis management in Australian aged care facilities: a mixed method study. (Pubmed Central) -  May 15, 2024   
    A need to raise awareness of aged care-specific consensus recommendations concerning vitamin D and calcium is evident. Facility protocols and procedures must be developed and implemented to ensure safe and effective use of denosumab.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target. (Pubmed Central) -  May 11, 2024   
    Bisphosphonates and denosumab significantly reduced the risk of vertebral fractures in patients with both obesity and T2DM...It is important to recognize elevated fracture risk and osteoporosis in obese and T2DM patients, as they are currently considered low risk and tend to be underdiagnosed and undertreated. The implementation of better diagnostic tools, including trabecular bone score, lumbar spine BMD/body mass index (BMI) ratio, and microRNAs to predict bone fragility, could improve fracture prevention in this patient group.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Modern treatment of unicameral and aneurysmatic bone cysts. (Pubmed Central) -  May 10, 2024   
    The historical treatment with intraosseous injection of methylprednisolone acetate into the bone cysts nowadays is reduced due to the morbidity of multiple injections and the risk of multiple pathologic fractures until the healing...Further studies are needed to confirm the effectiveness of denosumab and its side effects on skeletally immature patients...For simple bone cysts, the combination of curettage, bone graft, and ESIN showed the best results. Sclerotherapy for ABC also shows promising results.
  • ||||||||||  Prolia (denosumab) / Amgen
    Observational data, Retrospective data, Journal:  Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study. (Pubmed Central) -  May 9, 2024   
    Across Spanish PC, we observed a large gap in the treatment and follow-up of elderly subjects experiencing a fragility fracture. Our data highlights the urgent need to improve secondary fracture prevention in PC.
  • ||||||||||  Prolia (denosumab) / Amgen
    Denosumab-Induced Severe Hypocalcemia with Recurrent Side Effects (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1652;    
    Denosumab-induced hypocalcemia is rare, but due to its severe effects on neuromuscular and cardiac function, patients should be counseled on the symptoms of hypocalcemia to ensure prompt medical evaluation. Ultimately, treatment for post-LTx osteoporosis should be individualized with consideration of specific medical history as well as routine monitoring of calcium levels when prescribed denosumab.
  • ||||||||||  Prolia (denosumab) / Amgen
    Effect of Denosumab on Mineral and Bone Disorder in Kidney Transplant Recipients: A Preliminary Study (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1644;    
    Our results suggested that Denosumab can reduce the level of bone turnover markers in kidney transplant recipients and has a good safety profile. The long-term effects on bone metabolism and bone mineral density after kidney tranplantation need to be further investigated.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective. (Pubmed Central) -  May 6, 2024   
    Of particular note, clinical and preclinical studies suggest that commonly prescribed osteoporosis drugs like bisphosphonates, intermittent parathyroid hormone, anti-sclerostin antibody, selective estrogen receptor modulators and anti-receptor activator of nuclear factor-kappa B ligand inhibitor denosumab may also relieve back pain. Here, we cite clinical and preclinical studies and include unpublished data to support the argument that a subset of these therapeutics for osteoporosis may alleviate low back pain by also targeting the IVD.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Journal:  3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. (Pubmed Central) -  May 2, 2024   
    3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition. (Pubmed Central) -  May 2, 2024   
    Furthermore, a rise in serum TRAP and RANKL levels are detected before markers of bone turnover used in current clinical practice. These mechanistic advances may provide insight into a more defined window of opportunity to intervene with sequential therapy following denosumab discontinuation.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial termination, Metastases:  SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) -  Apr 25, 2024   
    P3,  N=595, Terminated, 
    Completed --> Terminated; Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a benefit for denosumab could be shown, these results would be of very limited clinical impact by the time they would be available
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Retrospective data, Journal:  The sequential antifracturative treatment: a meta-analysis of randomized clinical trials. (Pubmed Central) -  Apr 24, 2024   
    In general, at 2?years after the switch from anabolic to antiresorptive drugs, a weighted BMD was increased at the lumbar spine, total hip, and femoral neck site. The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or 'bone builders' in patients with very high or imminent risk of fracture.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Bone loss after discontinuation of denosumab: the devil is in the details. (Pubmed Central) -  Apr 21, 2024   
    Bone turnover markers were appropriately suppressed and bone mineral density increased in the spine and hip. This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab-induced bone changes in a child: a case report. (Pubmed Central) -  Apr 20, 2024   
    This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications. We present the case of a 9-year-old girl who developed striking bone changes following two years of denosumab therapy for giant cell lesions of the jaw.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review. (Pubmed Central) -  Apr 13, 2024   
    Delayed moderate to severe hypercalcaemia (serum calcium?>?3.0 mmol/l) due to teriparatide is rare but may lead to therapy withdrawal. The underlying predisposing risk factors remain unclear and highlight the importance of a routine serum calcium assessment on therapy.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review. (Pubmed Central) -  Apr 13, 2024   
    Physicians and dentists should provide comprehensive information to patients prescribed with antiresorptive drugs, emphasizing the need for an awareness of the risks of MRONJ in the context of osseointegrated implants. A longer term of follow-up is recommended to identify and manage MRONJ around dental implants in an early manner.
  • ||||||||||  Prolia (denosumab) / Amgen
    Embolization of huge giant cell tumor () -  Apr 10, 2024 - Abstract #ECIO2024ECIO_479;    
    However, the drug caused mandibular osteonecrosis, necessitating treatment withdrawal. Due to the location, size, and marked vascularity, embolization was chosen as therapeutic option.